Table 3.
Prognostic performance of active ratio and other biomarkers in the ascites fluid from ovarian cancer patients to distinguish between benign and malignant.
| Biomarkers (Cut-Off Points) | Specificity % (95% CI) |
Sensitivity % (95% CI) |
AUC | PPV | NPV |
|---|---|---|---|---|---|
| Active Ratio | |||||
| <1.43 | 90.0 (78.6–95.7) | 63.5 (56.6–69.9) | 0.8617 | 80.4 | 79.2 |
| <1.25 | 96.0 (86.5–99.3) | 52.0 (45.1–58.8) | 89.4 | 75.5 | |
| Total CXCL10 (pg mL−1) | |||||
| >241 | 90.2 (79.0–95.7) | 51.0 (44.2–57.6) | 0.8122 | 77.1 | 74.0 |
| >1204 | 94.1 (84.1–98.4) | 19.5 (14.7–25.4) | 68.2 | 64.4 | |
| Active CXCL10 (pg mL−1) | |||||
| >598 | 90.1 (80.4–96.1) | 35.6 (29.4–42.3) | 0.7872 | 70.0 | 68.4 |
| >1400 | 94.6 (85.2–98.5) | 17.3 (12.8–23.0) | 67.5 | 63.9 | |
| DPP4 (ng mL−1) | |||||
| >316 | 89.6 (77.8–95.5) | 12.2 (7.8–18.4) | 0.5598 | 43.2 | 61.2 |
| >389 | 95.8 (86.0–99.3) | 7.4 (4.2–12.8) | 53.3 | 61.5 | |
| Plasma CA125 (U mL−1) | |||||
| >548 | 90.0 (73.5–97.9) | 52.1 (44.7–59.5) | 0.8262 | 77.1 | 74.4 |
| >757 | 93.3 (77.9–99.2) | 44.7 (37.4–52.1) | 89.8 | 73.0 | |
| Combined Biomarkers | |||||
|
Active ratio & DPP4 (<1.43 and > 316 ng mL−1) |
91.7 (73.0–99.0) | 77.3 (68.3–84.7) | 0.9114 | 85.8 | 86.2 |
|
Active ratio & DPP4 (<1.25 and > 389 ng mL−1) |
95.8 (78.9–99.9) | 67.3 (57.7–75.9) | 91.2 | 81.9 | |
|
Active ratio & plasma CA125 (<1.43 and > 548 U mL−1) |
91.7 (70.3–86.3) | 79.1 (70.3–86.3) | 0.9337 | 86.1 | 87.1 |
|
Active ratio & plasma CA125 (<1.25 and > 757 U mL−1) |
95.8 (78.9–99.9) | 51.8 (42.1–61.5) | 88.9 | 75.4 | |
|
Active ratio & DPP4 & plasma CA125 (<1.43 and > 316 ng mL−1 and > 548 U mL−1) |
91.7 (73.0–99.0) | 90.0 (82.8–94.9) | 0.9511 | 87.5 | 93.4 |
|
Active ratio & DPP4 & plasma CA125 (<1.25 and > 389 ng mL−1 and > 757 U mL−1) |
95.8 (78.9–99.9) | 81.8 (73.3–88.5) | 93.4 | 94.7 |